stockportfolio.pro
Stocks / ABT vs GILD
ABT vs GILD
Abbott Laboratories and Gilead Sciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Abbott Laboratories (ABT) | Gilead Sciences, Inc. (GILD) | |
|---|---|---|
| Market cap | $158.9B | $155.8B |
| Revenue (latest FY) | $44.33B | $29.44B |
| Net income (latest FY) | $6.52B | $8.51B |
| Revenue growth (5y CAGR) | 5.1% | 3.6% |
| Net margin | 14.7% | 28.9% |
| Return on equity | 12.5% | 37.5% |
| P/E ratio | 25.3 | 17.1 |
| Dividend yield | 2.8% | 2.6% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABT — free Open GILD — freeFrequently asked questions
Which is bigger, ABT or GILD?
Abbott Laboratories is larger by market capitalization — $158.9B versus $155.8B.
Which grows faster, ABT or GILD?
Over the last five fiscal years, Abbott Laboratories grew revenue faster — 5.1%/yr versus 3.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.